Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab in Biomarker-Selected Advanced Solid Tumors
NCT04087018Phase 1Completed
- Sponsor
- Arcus Biosciences
- Start
- Sep 2019
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of zimberelimab in solid tumor (advanced stage) (2 arms), sponsored by Arcus Biosciences. Primary endpoint: Objective Response Rate at 12 months. Started Sep 2019; status: completed.
02
Drugs
zimberelimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04087018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04087018.